These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 17410020)
1. Safety profile of erlotinib in patients with advanced non-small cell lung cancer with chronic renal failure. Gridelli C; Maione P; Galetta D; Rossi A J Thorac Oncol; 2007 Jan; 2(1):96-8. PubMed ID: 17410020 [No Abstract] [Full Text] [Related]
2. Erlotinib effective against refractory bronchorrhea from advanced non-small cell lung cancer. Thotathil Z; Long J J Thorac Oncol; 2007 Sep; 2(9):881-2. PubMed ID: 17805071 [No Abstract] [Full Text] [Related]
3. Lung cancer response to gefitinib, then erlotinib, then gefitinib again. Wong AS; Seto KY; Chin TM; Soo RA J Thorac Oncol; 2008 Sep; 3(9):1077-8. PubMed ID: 18758318 [No Abstract] [Full Text] [Related]
4. Safety profiles of erlotinib therapy in patients with advanced non-small-cell lung cancer. Hotta K; Kiura K Expert Rev Anticancer Ther; 2011 Jul; 11(7):991-7. PubMed ID: 21806322 [TBL] [Abstract][Full Text] [Related]
5. Two generations of light/never-smokers with advanced adenocarcinoma of the lung with durable responses to erlotinib. Pennell NA; Yin L; Keshtgarpour M; Ma PC J Thorac Oncol; 2012 Jul; 7(7):1200-1. PubMed ID: 22706608 [No Abstract] [Full Text] [Related]
6. Erlotinib in patient with non-small cell lung cancer: significant symptomatic improvement within a few days but without change in chest X-ray. Garfield D; Kashef G Lung Cancer; 2006 Mar; 51(3):389-90. PubMed ID: 16359750 [No Abstract] [Full Text] [Related]
7. Three cases of long-lasting tumor control with erlotinib after progression with gefitinib in advanced non-small cell lung cancer. Gridelli C; Maione P; Galetta D; Colantuoni G; Del Gaizo F; Ferrara C; Guerriero C; Nicolella D; Rossi A J Thorac Oncol; 2007 Aug; 2(8):758-61. PubMed ID: 17762344 [TBL] [Abstract][Full Text] [Related]
8. Independent review of interstitial lung disease associated with death in TRIBUTE (paclitaxel and carboplatin with or without concurrent erlotinib) in advanced non-small cell lung cancer. Yoneda KY; Shelton DK; Beckett LA; Gandara DR J Thorac Oncol; 2007 Jun; 2(6):537-43. PubMed ID: 17545850 [TBL] [Abstract][Full Text] [Related]
9. Safety of concomitant administration of seasonal and/or H1N1 flu vaccination in patients receiving erlotinib for advanced non-small cell lung cancer. Spitaleri G; Delmonte A; Toffalorio F; De Pas TM; Gregorc V J Thorac Oncol; 2010 May; 5(5):752-4. PubMed ID: 20421772 [No Abstract] [Full Text] [Related]
10. Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study. Reck M; van Zandwijk N; Gridelli C; Baliko Z; Rischin D; Allan S; Krzakowski M; Heigener D J Thorac Oncol; 2010 Oct; 5(10):1616-22. PubMed ID: 20736854 [TBL] [Abstract][Full Text] [Related]
11. Clinical utility of epidermal growth factor receptor expression for selecting patients with advanced non-small cell lung cancer for treatment with erlotinib. Clark GM; Zborowski DM; Culbertson JL; Whitehead M; Savoie M; Seymour L; Shepherd FA J Thorac Oncol; 2006 Oct; 1(8):837-46. PubMed ID: 17409968 [TBL] [Abstract][Full Text] [Related]
12. Erlotinib after failure of gefitinib in patients with advanced non-small cell lung cancer previously responding to gefitinib. Vasile E; Tibaldi C; Chella A; Falcone A J Thorac Oncol; 2008 Aug; 3(8):912-4. PubMed ID: 18670311 [TBL] [Abstract][Full Text] [Related]
13. Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer. Lee E; Keam B; Kim DW; Kim TM; Lee SH; Chung DH; Heo DS J Thorac Oncol; 2013 Aug; 8(8):1069-74. PubMed ID: 23804027 [TBL] [Abstract][Full Text] [Related]
14. Modern treatment of lung cancer: case 2. Response to erlotinib after failure of gefitinib in a patient with advanced non-small-cell lung carcinoma. Garfield DH J Clin Oncol; 2005 Oct; 23(30):7738-40. PubMed ID: 16234533 [No Abstract] [Full Text] [Related]
15. Erlotinib in lung cancer. Pao W; Ladanyi M; Miller VA; N Engl J Med; 2005 Oct; 353(16):1739-41; author reply 1739-41. PubMed ID: 16240471 [No Abstract] [Full Text] [Related]
17. Erlotinib in lung cancer. Takano T; Ohe Y N Engl J Med; 2005 Oct; 353(16):1739-41; author reply 1739-41. PubMed ID: 16240472 [No Abstract] [Full Text] [Related]
18. Efficacy of gefitinib in a patient with lung cancer associated with idiopathic pulmonary fibrosis. Kishi K; Nakata K; Yoshimura K J Thorac Oncol; 2006 Sep; 1(7):733-4. PubMed ID: 17409949 [No Abstract] [Full Text] [Related]
19. Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer. Wong AS; Soong R; Seah SB; Lim SW; Chuah KL; Nga ME; Chin TM; Soo RA J Thorac Oncol; 2008 Apr; 3(4):400-4. PubMed ID: 18379359 [TBL] [Abstract][Full Text] [Related]
20. Mind your elders: therapeutic implications of epidermal growth factor receptor inhibition in older patients with advanced non-small-cell lung cancer. Langer CJ J Clin Oncol; 2007 Mar; 25(7):751-3. PubMed ID: 17228017 [No Abstract] [Full Text] [Related] [Next] [New Search]